Source:http://linkedlifedata.com/resource/pubmed/id/12679437
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-4-7
|
pubmed:abstractText |
To better understand the relations among leptin, insulin, and body fat during the metabolic progression to diabetes and during drug monotherapy, metabolic parameters were examined in subjects classified as 1) type 2 diabetes; 2) impaired fasting glucose or mild diabetes mellitus; 3) nondiabetic, matched for body mass index (BMI); and 4) nonobese, nondiabetic. Diabetic subjects were also studied during no pharmacological treatment, after 3 months of randomization to metformin or glyburide, and after 3 months of cross-over to the opposite drug. Log leptin correlated more with percent body fat (slope, 0.042; confidence interval, 0.036-0.047; r(2) = 0.826; P < 0.0001) than with total fat mass, percent truncal or nontruncal fat, or BMI. When normalized to percent fat, leptin did not differ by gender. Leptin normalized to percent fat was 35% less in untreated diabetes than that in BMI-matched controls (P < 0.001). Leptin normalized to percent fat was increased by 25% (P < 0.01) as a result of glyburide therapy compared with pretreatment values, but was unchanged by therapy with metformin. Across a spectrum of subjects with diabetes, impaired fasting glucose/mild diabetes, or BMI-matched nondiabetic controls, normalized leptin significantly correlated with glucose-induced insulin release, but not with insulin sensitivity. Our data suggest that plasma leptin is reduced in untreated type 2 diabetes probably as a consequence of reduced insulin secretion and that circulating leptin concentrations are differentially affected by monodrug therapy.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Nonesterified,
http://linkedlifedata.com/resource/pubmed/chemical/Glyburide,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Leptin,
http://linkedlifedata.com/resource/pubmed/chemical/Metformin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0021-972X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1543-53
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12679437-Adipose Tissue,
pubmed-meshheading:12679437-Body Composition,
pubmed-meshheading:12679437-Body Mass Index,
pubmed-meshheading:12679437-Cholesterol, HDL,
pubmed-meshheading:12679437-Cross-Over Studies,
pubmed-meshheading:12679437-Diabetes Mellitus, Type 2,
pubmed-meshheading:12679437-Fatty Acids, Nonesterified,
pubmed-meshheading:12679437-Female,
pubmed-meshheading:12679437-Glyburide,
pubmed-meshheading:12679437-Hemoglobin A, Glycosylated,
pubmed-meshheading:12679437-Humans,
pubmed-meshheading:12679437-Hypoglycemic Agents,
pubmed-meshheading:12679437-Insulin,
pubmed-meshheading:12679437-Leptin,
pubmed-meshheading:12679437-Male,
pubmed-meshheading:12679437-Metformin,
pubmed-meshheading:12679437-Middle Aged
|
pubmed:year |
2003
|
pubmed:articleTitle |
Leptin and body fat in type 2 diabetes and monodrug therapy.
|
pubmed:affiliation |
Department of Internal Medicine, Division of Endocrinology, Iowa City Veterans Affairs Medical Center and University of Iowa, Iowa City, Iowa 52246, USA. william-sivitz@uiowa.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|